



(11)

EP 3 126 383 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73, 74

(51) Int Cl.:
C07K 16/00 (2006.01)

(86) International application number:
PCT/US2015/024149

(48) Corrigendum issued on:
27.02.2019 Bulletin 2019/09

(87) International publication number:
WO 2015/153912 (08.10.2015 Gazette 2015/40)

(45) Date of publication and mention
of the grant of the patent:
19.12.2018 Bulletin 2018/51

(21) Application number: **15718304.7**

(22) Date of filing: **02.04.2015**

(54) **MODIFIED J-CHAIN**
MODIFIZIERTE J-KETTE
CHAÎNE J MODIFIÉE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Mewburn Ellis LLP**
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(30) Priority: **03.04.2014 US 201461974738 P**

(56) References cited:
WO-A1-98/30592 US-A1- 2003 224 443

(43) Date of publication of application:
08.02.2017 Bulletin 2017/06

(60) Divisional application:
18212426.3

(73) Proprietor: **IGM Biosciences, Inc.**
Mountain View, CA 94043 (US)

- **LIU XIAN-HUA ET AL: "[Expression of alpha-defensin-1 with J chain in the transfected COS-7 cells].", ZHONGGUO WEI ZHONG BING JI JIU YI XUE = CHINESE CRITICAL CARE MEDICINE = ZHONGGUO WEIZHONGBING JIJU YIXUE FEB 2006, vol. 18, no. 2, February 2006 (2006-02), pages 71-73, XP002743330, ISSN: 1003-0603**
- **J SYMERSKY ET AL: "Expression of the recombinant human immunoglobulin J chain in Escherichia coli", MOLECULAR IMMUNOLOGY, vol. 37, no. 3-4, 1 February 2000 (2000-02-01), pages 133-140, XP55207594, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(00)00035-3**

(72) Inventors:

- **KEYT, Bruce**
Hillsborough, CA 94010 (US)
- **PRESTA, Leonard, George**
San Francisco, CA 94109 (US)
- **ZHANG, Fen**
San Francisco, CA 94127 (US)
- **BALIGA, Ramesh**
Redwood City
California 94062 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 126 383 B8

- | | |
|--|---|
| <ul style="list-style-type: none"> • FOURNIER PHILIPPE ET AL: "Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 27, no. 1, 1 February 2013 (2013-02-01), pages 35-53, XP009178816, ISSN: 1173-8804, DOI: 10.1007/S40259-012-0008-Z • RAJU T SHANTHA ET AL: "Potential therapeutic roles for antibody mixtures", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 13, no. 10, 1 October 2013 (2013-10-01), pages 1347-1352, XP009179416, ISSN: 1744-7682 | <ul style="list-style-type: none"> • SUMIT GOSWAMI ET AL: "Developments and Challenges for mAb-Based Therapeutics", ANTIBODIES, vol. 2, no. 3, 16 August 2013 (2013-08-16) , pages 452-500, XP055128980, DOI: 10.3390/antib2030452 |
|--|---|